Breathe Easier: Can Exercise Improve Lung Health in Cystic Fibrosis?
"New research explores how a personalized exercise program can help those with cystic fibrosis improve lung function and overall well-being."
Cystic Fibrosis (CF) is a genetic disorder that primarily affects the lungs, leading to a buildup of thick mucus that can cause breathing difficulties and increase the risk of infections. While medical treatments have advanced, physical activity (PA) and exercise are increasingly recognized as vital components of CF care.
Regular physical activity offers numerous benefits for individuals with CF, including improved lung function, increased physical fitness, and enhanced quality of life. However, motivating people to be more active can be difficult. Supervised exercise programs can be expensive and time-intensive, leading to adherence challenges once the supervision ends. Unsupervised programs are more flexible, but maintaining compliance can be problematic.
The ACTIVATE-CF study, a large international multi-center randomized controlled trial, seeks to evaluate the effects of a partially supervised exercise intervention, combined with regular motivation, on lung health in a large group of CF patients. This article explores the study's design, methods, and potential impact on the lives of those living with CF.
Exercise and Lung Health in CF
Physical activity is described as one of the five most important treatments by people with cystic fibrosis (CF), and it can help alleviate exertional breathlessness and improve exercise tolerance. Regular activity may also slow pulmonary-function decline by supporting sputum clearance. A 2022 systematic review set out to assess exercise interventions’ effects on physical condition and lung function in children and adults with CF, but the provided summary gives no numerical effect estimates. The 2024 Cystic Fibrosis National Indicator Report describes national and state trends in diagnosis, treatment, demographics, nutrition, and lung health in the United States.
Exercise Within CF Care
The European Cystic Fibrosis Society Exercise Working Group, including members of its Physiotherapy Special Interest Group, developed guidance and standard operating procedures for selected exercise tests. The source describes exercise physiology as limited and less established alongside standard CF therapies, even as highly effective CFTR modulator therapies have changed clinical care. Exercise can offer benefits, but safety precautions are important for people with CF. The provided source summaries do not specify the particular tests or precautions.
ACTIVATE-CF: A Personalized Approach to Exercise
The ACTIVATE-CF study aims to determine if a tailored exercise program can improve lung function, measured by forced expiratory volume in one second (FEV1), in CF patients. Secondary goals include assessing the program's impact on health-related quality of life (HRQoL), anxiety and depression levels, and blood sugar control.
- Intervention Group: Receives individual counseling to increase vigorous PA by at least 3 hours per week, documents daily PA and inactivity, uses a step counter to track progress, and receives monthly phone calls for support.
- Control Group: Receives standard care and maintains their current PA levels during the study period. After 12 months, the control group also receives the intervention.
Research Gaps and Activity Tracking
A review on cardiopulmonary exercise testing and pulmonary exacerbations notes that evidence-based trials confirming early findings on exercise training and exercise capacity in CF remain limited; it identifies exacerbation risk as a priority for future research. The ACTIVATE-CF study randomized 117 children aged 12 or older and adults to a 12-month, partially supervised vigorous-activity intervention, but its body-composition data, collected as a secondary outcome, had not yet been reported in the cited review. A separate review describes ACTIVATE-CF as using pedometers and daily web-based exercise logs alongside standard care that included counseling every three months.
Limits, Tolerance, and Outcomes
The ACTIVATE-CF protocol notes that FEV1 has limitations as a clinical endpoint, although it remains the most commonly used endpoint in CF trials and the single best prognostic factor for CF. The trial’s stated aim was to test whether regular vigorous habitual physical activity could prevent FEV1 decline over time, rather than merely produce short-term improvement. CF lung disease can also cause abnormal breathing during exercise, limiting participation and affecting health and body image. A 2024 report says regular, especially more vigorous, activity is important for lung health and quality of life in adolescents and adults with CF, but the supplied summary does not provide effect sizes.
Exercise and Airway Clearance
Cochrane sources describe multiple accepted airway clearance techniques (ACTs) for respiratory health in CF, with none shown to be superior to the others. Other Cochrane reviews have reported short-term effects related to mucus transport but found no evidence supporting long-term benefits. Exercise is considered an alternative ACT and is thought to create shearing forces within lung tissue. The supplied material describes a review intended to compare exercise with other ACTs, but it does not report comparative trial results.
The Future of CF Care: Personalized Exercise and Technology
The ACTIVATE-CF study is significant because it is the first large, international study to investigate the effects of a personalized PA intervention on various health outcomes in CF, utilizing modern technology. If successful, this relatively simple program could be implemented on a wider scale internationally.
Telemedicine-Based Exercise
A systematic review set out to evaluate physiotherapy exercises delivered via telemedicine for people with cystic fibrosis. Its stated outcomes were lung function and quality of life. The review searched AMED, CINAHL, and MEDLINE, with the supplied summary indicating that the search period began in December. The available source material does not report the review’s findings or the search’s end date.
Real-World ETI Outcomes and Exercise Evidence
A 2025 real-world study reported that the impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on ppFEV1, hospitalizations, pulmonary exacerbations, and outpatient visits was consistent regardless of prior CFTR modulator treatment history. The study’s authors described reduced healthcare-resource use as evidence of ELX/TEZ/IVA’s transformative impact. Separately, a 2025 analysis used two French real-world observational studies to examine sweat chloride concentrations after ETI initiation in adults with at least one F508del variant and in people aged six or older without F508del treated through France’s compassionate program. The available summary does not provide the analysis’s results or establish how ETI affects exercise function.
This study also highlights the importance of patient-centered care. By tailoring exercise plans to individual preferences and providing ongoing support, the ACTIVATE-CF study aims to improve adherence and long-term outcomes.
As the study progresses, the results will offer valuable insights into the potential of personalized exercise programs to improve lung health and overall well-being in individuals with CF. By combining exercise with modern technology, the ACTIVATE-CF study could pave the way for more effective and accessible CF care.